$38m jump-start for MyoKardia as it pursues cardiomyopathy niche
This article was originally published in Scrip
Executive Summary
US startup MyoKardia has raised $38 million from a Series A financing without a compound singled out as a lead drug candidate, but by leveraging the expertise of its scientific founders the San Francisco-based company is targeting the eight genes connected to hundreds of genetic mutations that cause hypertrophic and dilated cardiomyopathies.